The Latest Breaking News from Vas Narasimhan

Trump says Europe does one thing right: drug prices. 'A pill that costs $10 in London costs $130 in New York or Los Angeles'

The president called out French President Emmanuel Macron on refusing to raise drug prices, and claimed tariff threats make Macron change his mind.

Fortune · Jan 21

Should You Buy Novartis Stock Before October 28?

Novartis is gaining traction this year, but can the trend continue?

Barchart · Oct 8, 2025

Novartis Builds US Drug Reserves Against Potential Tariffs

Novartis AG (NYSE:NVS) has reportedly built up its pharmaceutical stockpiles in the U.S. as a cushion against the potential impact of tariffs under consideration by the Trump administration, chief executive Vas Narasimhan said in a recent interview.

Benzinga · Sep 22, 2025

Molecular Partners, Novartis Note EUA For COVID-19 Therapy May Need Additional Data

Molecular Partners AG (NASDAQ:MOLN) has provided an update regarding the Emergency Use Application (EUA) for ensovibep, a DARPin antiviral therapeutic candidate to treat COVID-19. The Company says that EUA, in review with the FDA, may require additional clinical data to be authorized. Vas Narasimhan also noted that the current omicron wave of SARS-Cov-2,…

Benzinga · Apr 27, 2022